싱그릭스와 조스타박스 백신 효능 비교

 

싱그릭스와 조스타박스 백신 효능 비교

Vaccine	Efficacy (incidence HZ)	Systemic side effects that prevented normal everyday activities (vaccine versus placebo)	Follow-up	Comment
ZVL (single dose)	Population ≥60 years of age[1]: 51% reduction in risk of HZ compared with placebo (95% CI 44.2-57.6%; 11.12 versus 5.42 per 1000 person-years)	<1% reported in post-hoc analysis[5]	3.1 years	Vaccine efficacy was significantly greater in individuals aged 60 to 69 years compared with those ≥70 years (63.9 versus 37.6%). Protection against postherpetic neuralgia was 67%[1]. Protection은 5년 동안 변하지 않는 것 같다. 그러나 8년 이후에는 의미 있게 감소하였다. Observational studies found the protection from ZVL wanes significantly after 5 to 8 years (from approximately 50% to 20 to 30% for those ≥60 years of age)[6-8]. 한 연구에서 8년 이후 PHN의 보호 효과는 부분적으로 남아 있을지라도 herpes zoster를 줄이는 이득은 없었다. Protection against postherpetic neuralgia was maintained significantly longer.
	Population 50 to 59 years of age[2]: 70% reduction in risk of HZ compared with placebo (95% CI 54.1-80.6%; 6.57 versus 1.99 per 1000 person-years)		1.3 years
RZV (2 doses separated by 2 months)	Population ≥70 years of age[3]: 89% reduction in risk of HZ compared with placebo (95% CI 84.2-93.7%; 9.2 versus 0.9 per 1000 person-years)	6 versus 2%	3.7 years	Myalgia was the most common systemic reaction. 7년 추적 관찰 동안 herpes zoster에 대한 효능과 면역반응은 높게 유지되었다 (84%, 91% : two trials). Protection against postherpetic neuralgia in patients ≥70 years of age was 89%.
	Population ≥50 years of age[4]: 96.2% reduction in risk of HZ compared with placebo (95% CI 92.7-98.3%; 9.1 versus 0.3 per 1000 person-years)	11.4 versus 2.4%	3.2 years

 

RZV: recombinant zoster vaccine; ZVL: zoster live vaccine; HZ: herpes zoster.

싱그릭스, 조스타박스

 

REF. UpToDate 2023.03.07